Loading...
•
Sep 30, 2022
Replimune Q2 2023 Earnings Report
Reported financial results for the fiscal second quarter and provided a business update.
Key Takeaways
Replimune Group announced financial results for the fiscal second quarter ended September 30, 2022. The company is focused on establishing oncolytic immunotherapies as a cornerstone treatment for solid tumor indications and plans to establish a major skin cancer franchise with RP1. They completed a $200 million term-loan that extended cash runway into 2025.
Completed enrollment in the CERPASS registration-directed clinical trial evaluating RP1 in cutaneous squamous cell carcinoma (CSCC); primary analysis data expected to be released in H1 2023.
Six-month follow-up data from the first 75 patients enrolled in the IGNYTE clinical trial cohort of RP1 combined with Opdivo® (nivolumab) in anti-PD1 failed melanoma expected by year end.
An update on the RP2/3 development program remains on track to be provided by year end.
Completed $200 million term-loan that extended cash runway into 2025.
Forward Guidance
The Company believes that existing cash, cash equivalents and short-term investments, as of September 30, 2022, together with unrestricted proceeds available to be drawn under the Hercules debt facility, will enable funding operations into calendar 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...